3-(6-tert-butyl-1,1-dimethyl-2,3-dihydroinden-4-yl)-5-(trifluoromethyl)-1H-pyrazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 3-(6-tert-butyl-1,1-dimethyl-2,3-dihydroinden-4-yl)-5-(trifluoromethyl)-1H-pyrazole
• 化学式: C₁₉H₂₃F₃N₂
• 分子量: 336.4
• InChiKey: JXYDPVVIKXTQIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• LXR AGONISTS FOR TREATING PSYCHIATRIC STRESS DISORDERS
  申请人：Yeda Research and Development Co. Ltd

  公开号：EP3821888A1

  公开（公告）日：2021-05-19

  Agents and methods of treating a psychiatric stress disorder, Rett syndrome, MeCP2 duplication syndrome or multiple sclerosis are provided. Accordingly there is provided an agent capable of down-regulating activity and/or expression of importin alpha5 for use in the treatment of a medical condition selected from the group consisting of psychiatric stress disorder, Rett syndrome, MeCP2 duplication syndrome and multiple sclerosis. Also provided are methods of identifying an agent that inhibits activity of importin alpha5. A combination of an agent capable of up-regulating activity and/or expression of liver X receptor (LXR) and a selective serotonin reuptake inhibitor (SSRI), for use in treating a psychiatric stress disorder in a subject in need thereof.

  提供了治疗精神应激障碍、Rett 综合征、MeCP2 重复综合征或多发性硬化症的制剂和方法。因此，提供了一种能够下调输入蛋白α5的活性和/或表达的制剂，用于治疗选自精神应激障碍、Rett综合征、MeCP2复制综合征和多发性硬化症的一组疾病。还提供了鉴定抑制输入蛋白α5活性的制剂的方法。一种能够上调肝X受体（LXR）活性和/或表达的制剂与一种选择性5-羟色胺再摄取抑制剂（SSRI）的组合，用于治疗有需要的受试者的精神应激障碍。
• NOVEL MOLECULES FOR REGULATING CELL DEATH
  申请人：Nunnari Jodi

  公开号：US20080287473A1

  公开（公告）日：2008-11-20

  The present invention provides compounds capable of regulating apoptosis, e.g., via regulating mitochondrial fission or fusion. The present invention also provides methods of screening for compounds capable of regulating apoptosis and methods of treating conditions association with apoptosis.
• Compositions and Methods for Increasing Stress Resilience
  申请人：The Children's Hospital of Philadelphia

  公开号：US20140309291A1

  公开（公告）日：2014-10-16

  Compositions and methods for increasing resilience to the effects of stress are provided.
• METHODS OF TREATING PSYCHIATRIC STRESS DISORDERS
  申请人：Yeda Research and Development Co. Ltd.

  公开号：US20200060994A1

  公开（公告）日：2020-02-27

  Agents and methods of treating a psychiatric stress disorder, Rett syndrome, MeCP2 duplication syndrome or multiple sclerosis are provided. Accordingly there is provided an agent capable of down-regulating activity and/or expression of importin alpha5 for use in the treatment of a medical condition selected from the group consisting of psychiatric stress disorder, Rett syndrome, MeCP2 duplication syndrome and multiple sclerosis. Also provided are methods of identifying an agent that inhibits activity of importin alpha5.
• US8450333B2
  申请人：——

  公开号：US8450333B2

  公开（公告）日：2013-05-28